Short Interest in Trinity Biotech PLC (NASDAQ:TRIB) Decreases By 56.9%

Trinity Biotech PLC (NASDAQ:TRIB) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 114,400 shares, a drop of 56.9% from the August 31st total of 265,300 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 5,020,000 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 5,020,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.7% of the company’s stock are short sold.

Trinity Biotech Trading Up 8.5%

TRIB opened at $1.15 on Friday. The business’s 50-day simple moving average is $3.19 and its 200-day simple moving average is $3.31. Trinity Biotech has a one year low of $0.48 and a one year high of $3.44.

Wall Street Analyst Weigh In

TRIB has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Trinity Biotech in a report on Saturday, September 27th. Zacks Research raised Trinity Biotech to a “hold” rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Trinity Biotech has a consensus rating of “Reduce”.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in shares of Trinity Biotech PLC (NASDAQ:TRIB) by 16.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 437,910 shares of the company’s stock after purchasing an additional 62,800 shares during the period. Hunter Associates Investment Management LLC owned about 2.43% of Trinity Biotech worth $284,000 at the end of the most recent reporting period. 78.97% of the stock is currently owned by hedge funds and other institutional investors.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.